OriCiro Genomics was a Japanese biotech startup founded in 2018 specializing in cell-free DNA assembly and amplification technology for synthetic biology. The company provided reagent kits, co-development services, and technology licensing for plasmid DNA manufacturing. Acquired by Moderna in 2023 for $85 million. Not a CDMO -- it was a technology/reagent provider for synthetic biology applications.
Cell-free DNA synthesis and amplification technology (no pharmaceutical manufacturing).
2 sites worldwide
No certifications on file yet.
No reviews available yet.
No documents available.